Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL V CHIOREAN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1578527099
CMS profile
116271
Location
ISSAQUAH, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$315,109.59

310 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $112,507.82 87
PFIZER INC. $56,125.74 43
Lilly USA, LLC $50,303.59 70
E.R. Squibb & Sons, L.L.C. $26,771.97 32
Takeda Pharmaceuticals U.S.A., Inc. $21,472.02 20
Janssen Biotech, Inc. $16,709.05 22
Janssen Scientific Affairs, LLC $12,540.20 16
Celgene Corporation $9,781.82 6
Celltrion USA Inc. $8,518.18 8
Laborie Medical Technologies Corp. $190.07 1
AIMMUNE THERAPEUTICS, INC. $93.95 2
3-D Matrix, Inc. $52.32 1
CapsoVision, Inc. $24.77 1
Merck Sharp & Dohme LLC $18.09 1

Page 2 of 7; records 51–100 of 310 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL V CHIOREAN

NPI 1578527099 · CMS profile ID 116271

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ISSAQUAH, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 7; records 51–100 of 310 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578527099?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL V CHIOREAN, NPI 1578527099, CMS profile ID 116271. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 310 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578527099?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MICHAEL V CHIOREAN, NPI 1578527099, CMS profile ID 116271. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 310 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578527099?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MICHAEL V CHIOREAN, NPI 1578527099, CMS profile ID 116271, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 310 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1578527099?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

310 matching records · $315,109.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 310 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 310.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $148.0009/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180536 CMS
ABBVIE INC. $10.7209/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180538 CMS
ABBVIE INC. $5,950.0009/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103145099 CMS
ABBVIE INC. $5,950.0009/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103145101 CMS
ABBVIE INC. $4,250.0009/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103145103 CMS
ABBVIE INC. $4,250.0009/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103145105 CMS
ABBVIE INC. $5,950.0009/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103145107 CMS
ABBVIE INC. $4,250.0009/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103145109 CMS
Lilly USA, LLC $28.8209/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135200933 CMS
ABBVIE INC. $125.0009/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103462030 CMS
ABBVIE INC. $918.7709/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180530 CMS
ABBVIE INC. $1,164.1909/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180532 CMS
E.R. Squibb & Sons, L.L.C. $4,829.0009/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101413079 CMS
ABBVIE INC. $28.2409/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103462026 CMS
ABBVIE INC. $123.7509/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103462028 CMS
ABBVIE INC. $543.2909/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180526 CMS
ABBVIE INC. $814.9309/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180528 CMS
Lilly USA, LLC $18.6009/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135198798 CMS
Lilly USA, LLC $21.4409/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135201273 CMS
Lilly USA, LLC $81.9709/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135225291 CMS
Lilly USA, LLC $82.0009/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135247864 CMS
ABBVIE INC. $80.1409/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103462024 CMS
ABBVIE INC. $1,011.1509/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180520 CMS
ABBVIE INC. $690.6309/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180522 CMS
ABBVIE INC. $831.5609/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180524 CMS
Lilly USA, LLC $2,800.0008/30/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135173094 CMS
Lilly USA, LLC $3,600.0008/30/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135234418 CMS
Celltrion USA Inc. $3,250.0008/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075849769 CMS
Celltrion USA Inc. $9.3608/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075849771 CMS
Celltrion USA Inc. $131.5208/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075849773 CMS
E.R. Squibb & Sons, L.L.C. $10.0508/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101413063 CMS
E.R. Squibb & Sons, L.L.C. $111.0008/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101413067 CMS
E.R. Squibb & Sons, L.L.C. $37.6208/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101413081 CMS
Lilly USA, LLC $5,200.0008/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135198796 CMS
E.R. Squibb & Sons, L.L.C. $1,641.0008/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101413057 CMS
E.R. Squibb & Sons, L.L.C. $1,641.0008/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101413069 CMS
E.R. Squibb & Sons, L.L.C. $1,894.0008/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101413075 CMS
Lilly USA, LLC $20.5008/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135247861 CMS
E.R. Squibb & Sons, L.L.C. $30.0008/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101413055 CMS
E.R. Squibb & Sons, L.L.C. $38.0008/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101413065 CMS
E.R. Squibb & Sons, L.L.C. $1,894.0008/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101413091 CMS
E.R. Squibb & Sons, L.L.C. $10.7208/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101413093 CMS
E.R. Squibb & Sons, L.L.C. $62.0208/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101413095 CMS
Lilly USA, LLC $474.2908/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135173074 CMS
Lilly USA, LLC $109.7708/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135173076 CMS
Lilly USA, LLC $39.5108/23/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155181461 CMS
Lilly USA, LLC $134.0008/23/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155181463 CMS
Lilly USA, LLC $22.1608/23/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155181621 CMS
Lilly USA, LLC $22.7808/23/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155181623 CMS
Lilly USA, LLC $22.7808/23/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155181781 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $164,803.82 162
PY2020 $87,901.90 81
PY2021 $106,413.95 102
PY2022 $257,264.91 281
PY2023 $213,844.86 198
PY2024 $315,109.59 310
PY2025 $279,277.98 268

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,410.00 4
PY2025 Principal investigator $74,323.36 23
PY2024 Recipient $5,580.00 5
PY2024 Principal investigator $111,620.44 35
PY2023 Recipient $17,480.00 17
PY2023 Principal investigator $102,116.98 70
PY2022 Recipient $17,360.00 13
PY2022 Principal investigator $155,415.20 53
PY2021 Recipient $15,000.00 9
PY2021 Principal investigator $509,301.55 108
PY2020 Recipient $3,491.46 6
PY2020 Principal investigator $716,019.13 180
PY2019 Recipient $546.51 10
PY2019 Principal investigator $766,569.51 164

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $840.00 12/23/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228740551
Recipient PFIZER INC. $3,200.00 12/22/2025 Covered Recipient Physician ETRASIMOD CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726878
Recipient PFIZER INC. $940.00 10/26/2025 Covered Recipient Physician ETRASIMOD CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727313
Principal investigator 1 PFIZER INC. $3,078.00 10/09/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228740342
Principal investigator 1 PFIZER INC. $1,000.00 08/01/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228719555
Principal investigator 1 PFIZER INC. $1,000.00 08/01/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228742786
Principal investigator 1 PFIZER INC. $1,000.00 08/01/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228742994
Principal investigator 1 PFIZER INC. $2,000.00 07/14/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228755524
Principal investigator 1 PFIZER INC. $75.00 07/02/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228755943
Principal investigator 1 PFIZER INC. $3,773.00 06/25/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228792377
Principal investigator 1 PFIZER INC. $500.00 06/20/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228792573
Principal investigator 1 PFIZER INC. $840.00 06/18/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228793379
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,500.00 06/05/2025 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223269372
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,800.00 06/05/2025 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223269374
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,500.00 06/05/2025 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223269376
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,000.00 06/05/2025 Covered Recipient Teaching Hospital
SWEDISH MEDICAL CENTER
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223269378
Recipient PFIZER INC. $940.00 05/04/2025 Covered Recipient Physician ETRASIMOD CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228771120
Recipient PFIZER INC. $330.00 04/24/2025 Covered Recipient Physician ETRASIMOD CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769076
Principal investigator 1 PFIZER INC. $1,507.00 04/11/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228791599
Principal investigator 1 PFIZER INC. $270.00 03/19/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228785744
Principal investigator 1 PFIZER INC. $2,500.00 03/17/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228722626
Principal investigator 1 PFIZER INC. $1,200.00 03/17/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228776993
Principal investigator 1 PFIZER INC. $500.00 03/17/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228776996
Principal investigator 1 PFIZER INC. $2,500.00 03/17/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228785261
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18,068.90 02/06/2025 Covered Recipient Teaching Hospital
Swedish Medical Center
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1236000176
Principal investigator 1 PFIZER INC. $840.00 02/03/2025 Covered Recipient Teaching Hospital
SWEDISH ISSAQUAH
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228777926
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $31.46 01/27/2025 Non-covered Recipient Entity
Swedish Gastroenterology
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235993391